ALKS
Price
$27.15
Change
+$0.04 (+0.15%)
Updated
Apr 23 closing price
Capitalization
4.55B
7 days until earnings call
DVAX
Price
$10.77
Change
+$0.05 (+0.47%)
Updated
Apr 23 closing price
Capitalization
1.62B
7 days until earnings call
Ad is loading...

ALKS vs DVAX

Header iconALKS vs DVAX Comparison
Open Charts ALKS vs DVAXBanner chart's image
Alkermes
Price$27.15
Change+$0.04 (+0.15%)
Volume$1.79M
Capitalization4.55B
Dynavax Technologies
Price$10.77
Change+$0.05 (+0.47%)
Volume$2.41M
Capitalization1.62B
ALKS vs DVAX Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. DVAX commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and DVAX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ALKS: $27.15 vs. DVAX: $10.77)
Brand notoriety: ALKS and DVAX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 97% vs. DVAX: 87%
Market capitalization -- ALKS: $4.55B vs. DVAX: $1.62B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. DVAX’s [@Pharmaceuticals: Other] market capitalization is $1.62B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 5 bearish.
  • DVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ALKS and DVAX are a bad buy in the short-term.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -0.18% price change this week, while DVAX (@Pharmaceuticals: Other) price change was +1.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.96%. For the same industry, the average monthly price growth was -6.07%, and the average quarterly price growth was -9.98%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

DVAX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.96% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than DVAX($1.62B). DVAX has higher P/E ratio than ALKS: DVAX (31.63) vs ALKS (8.90). ALKS YTD gains are higher at: -5.598 vs. DVAX (-15.662). ALKS has higher annual earnings (EBITDA): 519M vs. DVAX (9.67M). ALKS (773M) and DVAX (742M) have equal amount of cash in the bank . DVAX has less debt than ALKS: DVAX (257M) vs ALKS (372M). ALKS has higher revenues than DVAX: ALKS (1.66B) vs DVAX (232M).
ALKSDVAXALKS / DVAX
Capitalization4.55B1.62B281%
EBITDA519M9.67M5,369%
Gain YTD-5.598-15.66236%
P/E Ratio8.9031.6328%
Revenue1.66B232M717%
Total Cash773M742M104%
Total Debt372M257M145%
FUNDAMENTALS RATINGS
ALKS vs DVAX: Fundamental Ratings
ALKS
DVAX
OUTLOOK RATING
1..100
1169
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
2656
SMR RATING
1..100
3584
PRICE GROWTH RATING
1..100
6178
P/E GROWTH RATING
1..100
1297
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (71) in the Biotechnology industry is in the same range as ALKS (99). This means that DVAX’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (26) in the Biotechnology industry is in the same range as DVAX (56). This means that ALKS’s stock grew similarly to DVAX’s over the last 12 months.

ALKS's SMR Rating (35) in the Biotechnology industry is somewhat better than the same rating for DVAX (84). This means that ALKS’s stock grew somewhat faster than DVAX’s over the last 12 months.

ALKS's Price Growth Rating (61) in the Biotechnology industry is in the same range as DVAX (78). This means that ALKS’s stock grew similarly to DVAX’s over the last 12 months.

ALKS's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for DVAX (97). This means that ALKS’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSDVAX
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
62%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
74%
View a ticker or compare two or three
Ad is loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JETU13.180.93
+7.59%
MAX Airlines 3X Leveraged ETN
ROUS48.740.53
+1.11%
Hartford Multifactor US Equity ETF
QWLD125.020.85
+0.69%
SPDR® MSCI World StrategicFactors ETF
PXI38.910.09
+0.24%
Invesco Dorsey Wright Energy MomentumETF
IBDV21.51N/A
N/A
iShares iBonds Dec 2030 Term Corp ETF

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with DVAX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+0.15%
DVAX - ALKS
34%
Loosely correlated
+0.47%
ESPR - ALKS
32%
Poorly correlated
+1.50%
VTRS - ALKS
32%
Poorly correlated
+1.56%
AMPH - ALKS
30%
Poorly correlated
-1.63%
ACET - ALKS
30%
Poorly correlated
+5.90%
More